1. [VEXAS syndrome : when do we have to consider it ?]
- Author
-
Coattrenec Y, De Lorenzi C, Samii K, Serratrice J, and Seebach JD
- Subjects
- Adult, Humans, Inflammation, Mutation, Pyoderma Gangrenosum, Ubiquitin-Activating Enzymes genetics, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics, Skin Diseases, Genetic diagnosis, Skin Diseases, Genetic drug therapy, Skin Diseases, Genetic genetics, Vasculitis
- Abstract
VEXAS syndrome was recently discovered in patients who developed late in adulthood an inflammatory syndrome with fever, cytopenias, dysplastic bone marrow, cutaneous and pulmonary neutrophilic inflammation, arthritis, chondritis, or vasculitis. It is the result of an inactivating somatic mutation affecting methionine codon 41 of the UBA1 gene which encodes an ubiquitin activating enzyme (E1). Systemic corticosteroids generally reduce symptoms, while other immunosuppressive drugs only have limited long-term effects. Azacitidine is a promising treatment, but further studies are warranted. Here, we describe 2 new cases including one associated with pyoderma gangrenosum and cryoglobulinemia., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2022
- Full Text
- View/download PDF